March 20 (Reuters) - Cardiome Pharma Corp:
* CIPHER PHARMACEUTICALS AND CARDIOME PHARMA ANNOUNCE STRATEGIC TRANSACTION FOR CANADIAN BUSINESS PORTFOLIO OF CARDIOME
* CIPHER PHARMACEUTICALS INC - DEAL PROVIDES IMPORTANT UPFRONT AND NON-DILUTIVE CONSIDERATION OF $25.5 MILLION CAD
* CIPHER PHARMACEUTICALS - ‍PROPOSED DEAL TO BE COMPLETED PURSUANT TO ACQUISITION BY CIPHER OF ALL OF CARDIOME SHARES, FOLLOWING RESTRUCTURING OF CARDIOME​
* CIPHER PHARMACEUTICALS - ‍CARDIOME SHAREHOLDERS TO GET SHARES, ON A ONE-FOR-ONE RATIO, OF NEWLY CREATED CANADIAN ENTITY NAMED CORREVIO PHARMA
* CIPHER PHARMACEUTICALS INC - BOARD OF DIRECTORS OF CARDIOME HAS UNANIMOUSLY APPROVED ARRANGEMENT AGREEMENT
* CIPHER PHARMACEUTICALS INC - ‍EXPECTS TO FINANCE ACQUISITION WITH A COMBINATION OF CASH AND NEW DEBT​
* CIPHER PHARMACEUTICALS - ‍ALL OF DIRECTORS AND SENIOR OFFICERS OF CARDIOME HAVE ENTERED INTO VOTING AND SUPPORT AGREEMENTS WITH CIPHER​
* CIPHER PHARMACEUTICALS - VOTING AND SUPPORT AGREEMENTS’ BY ‍ALL OF DIRECTORS AND SENIOR OFFICERS OF CARDIOME IS TO VOTE IN FAVOUR OF ARRANGEMENT​ Source text for Eikon: Further company coverage: